ADLM 2026 highlighted five forces transforming diagnostic development: artificial intelligence, decentralized testing, actionable biomarkers, greater accessibility, and demand for better clinical cohorts.
A targeted prospective study delivered high-viability PBMCs and clinical data from donors with Graves disease, thyroid eye disease, and active orbitopathy.
A targeted rheumatic heart disease and matched healthy-control serum collection completed in approximately two months.
Learn how Boca Bio successfully completed a prospective collection of 500 plasma specimens from healthy adults aged 60+ across six U.S. clinical sites. Discover how standardized plasma processing, multi-site clinical operations, and sponsor-specific protocols supported high-quality biospecimens for biomarker research.
High-quality HIV biospecimens are essential for developing and validating accurate diagnostic assays. A recent peer-reviewed study published in the Journal of Clinical Virology Plus demonstrated excellent analytical and clinical agreement for the Siemens Healthineers HIV Antigen/Antibody Combo assay across multiple automated testing platforms. The study utilized well-characterized HIV-positive and HIV-negative serum specimens, including samples sourced from Boca Biolistics, highlighting the critical role of quality biospecimens in assay verification and clinical validation. Boca Bio supports diagnostics manufacturers, biotechnology companies, and clinical research organizations with customized HIV biospecimen procurement, central laboratory services, and clinical research solutions that help accelerate infectious disease diagnostic development and regulatory submissions.
Clinical trial success depends on more than patient recruitment. Learn why high-quality clinical data, biospecimen integrity, and operational excellence are becoming critical competitive advantages in modern clinical research.
Selecting the right biospecimen and lab testing services partner is critical for generating reliable data, accelerating timelines, and supporting regulatory success. This blog outlines seven key factors pharma and IVD teams should evaluate, including biospecimen access, CLIA-certified testing, biomarker expertise, regulatory experience, data traceability, and integrated laboratory services. Learn how the right partner can help streamline research operations and improve study outcomes.
Learn how Boca Bio helped a next-generation drug discovery company complete a chronic migraine biomarker study within two months through high-quality biospecimen collection, multi-site patient recruitment, and precise sample handling that preserved biomarker integrity.
A global diagnostics company accelerated FDA approval and market launch for 12 infectious disease tests by partnering with Boca Bio. Facing delays from slow, inflexible vendors, the company needed rapid sample sourcing, faster testing, and agile clinical support. Boca Bio delivered results up to 12x faster, reduced site activation timelines by half, and ensured compliance with strict FDA deadlines—enabling earlier market entry and improved revenue outcomes.
A global diagnostics company accelerated FDA approval and market launch for 12 infectious disease tests by partnering with Boca Bio. Facing delays from slow, inflexible vendors, the company needed rapid sample sourcing, faster testing, and agile clinical support. Boca Bio delivered results up to 12x faster, reduced site activation timelines by half, and ensured compliance with strict FDA deadlines—enabling earlier market entry and improved revenue outcomes.